PDF(Pubmed)
Abstract：
The newly released nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) in the 2023 European Association for the Study of the Liver Congress has raised great clinical concerns. This marks the second instance of significant renaming of non-alcoholic fatty liver disease since the introduction of metabolic dysfunction-associated fatty liver disease (MAFLD) in 2020. The nomenclature and definitions of MASLD and MAFLD exhibit significant disparities as well as substantial consensus. The disparities regarding the framework of nomenclature, the definitions, the clinical management, and the impact on the clinical outcomes between MASLD and MAFLD were comprehensively compared in this editorial. Additionally, the consensus reached by the MASLD and MAFLD definitions also emphasizes positive diagnosis rather than negative diagnosis within the framework of establishing a diagnostic approach. Furthermore, they acknowledged the pivotal role of metabolic dysfunction in the pathogenesis of MAFLD or MASLD and the positive role of increasing the awareness of the disease in public. Fortunately, the non-invasive tests remains effective in the MASLD and MAFLD era. Elucidating these disparities would contribute to a more comprehensive comprehension of the nature of steatotic liver disease and enhance clinical practice. Thus, more efforts are required to reach more consensus about these important topics.
摘要：
2023年欧洲肝脏大会研究协会新发布的代谢功能障碍相关脂肪变性肝病（MASLD）命名法引起了极大的临床关注。这标志着自2020年引入代谢功能障碍相关脂肪性肝病（MAFLD）以来，非酒精性脂肪性肝病的第二次重大更名。MASLD和MAFLD的命名和定义表现出显著的差异以及实质性的共识。关于命名框架的差异，定义,临床管理，并在这篇社论中全面比较了MASLD和MAFLD对临床结局的影响。此外,在建立诊断方法的框架内,MASLD和MAFLD定义达成的共识还强调阳性诊断而非阴性诊断.此外，他们承认代谢功能障碍在MAFLD或MASLD发病机制中的关键作用,以及提高公众对该疾病认识的积极作用.幸运的是,非侵入性测试在MASLD和MAFLD时代仍然有效。阐明这些差异将有助于更全面地理解脂肪变性肝病的性质并增强临床实践。因此，需要做出更多努力，就这些重要议题达成更多共识。
